Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "Thymosin α1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Solid phase synthetic technique for thymosin alpha1
ActiveCN101104638AAdvantages of solid phase synthesis processEasy to purifyThymopoietinsPeptide preparation methodsFluoroacetic acidAcetic anhydride
The invention relates to a solid-phase synthesis process of a thymosin alpha 1, belonging to the polypeptide solid-phase synthesis technical field. The invention comprises the following steps: a. a Fmoc-Rink Amide AM resin or a Fmoc-Rink Amide MBHA resin is used as carrier, an H2N-Rink Amide AM resin or an H2N-Rink Amide MBHA resin is obtained after deprotection of the Fmoc; b. side chain carboxyl group of Fmoc-Asp-X is connected with resin amino by the method of solid-phase synthesis to obtain the Fmoc-Asp (resin)-X; c. the left amino acid in the sequence is synthesized in solid-phase with the Fmoc strategy; d. after the amino protection group Fmoc of N terminal amino acid is removed, the N terminal amino acid is acetylated by acetic anhydride and pyridine; e. then the acetylated N terminal amino acid is cut by a cracking agent (tri fluoroacetic acid / benzoylate sulfide / 1, 2- dithioglycol / Anisole) to obtain the thymosin alpha 1; f. crude product of the thymosin alpha 1 is prepared and separated by HPLC to obtain the pure thymosin alpha 1. The invention can increase significantly the yield of the thymosin alpha 1 and decrease the production cost, which is helpful for scale production and has better industrialization prospect.
Owner:苏州天马医药集团天吉生物制药有限公司
Solid Phase Synthesis of Thymosin α1
ActiveCN102286091ASimple and fast operationMild reaction conditionsHormone peptidesPeptide preparation methodsCombinatorial chemistrySolid-phase synthesis
The invention relates to a solid phase synthesis process of thymosin alpha1. The process comprises the following steps of: (1) preparation of NH2-Asn(Trt)-CTC resin; (2) synthesis of AA(1-27)-Asn(Trt)28-CTC resin; (3) preparation of Ac-AA(1-27)-Asn28(Trt)-CTC resin; (4) preparation of crude thymosin alpha1 by using a cracking agent; and (5) purification of the crude thymosin alpha1.
Owner:HARBIN PHARMA GROUP BIOLOGICAL ENG +1
Immunotherapy for reversing immune suppression
InactiveUS7731945B2Restoring T cell immunityPromoting differentiationAntibacterial agentsOrganic active ingredientsRegion lymph nodeDendritic cell
A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α1.
Owner:BROOKLYN IMMUNOTHERAPEUTICS LLC
Polyethylene glycol derivatives of thymosin alphal
InactiveCN1532207AModified implementationThymopoietinsPeptide/protein ingredientsSmall-cell carcinomaMelanoma
The present invention relates to polyethylene glycol derivatives of thymosin alpha-1, their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, malignant melanoma, non-small cell lung carcinoma, SARS, etc.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Immunotherapy for reversing immune suppression
InactiveUS20110044941A1Promoting differentiation and maturationRestore immunityAntibacterial agentsOrganic active ingredientsRegion lymph nodeDendritic cell
A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α1.
Owner:IMMUNO RX
Method and special engineering bacteria for producing N-terminal acetyl protein or polypeptide
ActiveCN101979505AOvercoming the inability to acetylateOvercomes the disadvantage of only partial acetylationHormone peptidesBacteriaNucleotideAmino acid
The invention discloses a method and special engineering bacteria for producing N-terminal acetyl protein or polypeptide. The recombinant engineering bacteria capable of expressing transferase of archaebacteria on chromosomes are obtained by integrating the expression box of the transferase of archaebacteria onto the chromosomes of a host; the expression box for expressing the transferase of archaebacteria comprises a promoter and an archaebacteria transferase gene connected with the downstream of the promoter; and the nucleotide sequence of the archaebacteria transferase gene is represented by the sequence No.1 in a sequence list, and the amino acid sequence of the archaebacteria transferase gene is represented by a sequence No.2 in a sequence table. The engineering bacteria of the invention can directly produce complete N-terminal acetyl protein or polypeptide, such as thymosin extrasin alpha 1 and thymosin extrasin beta 4, the drawback of incompetence of acetylation or partial acetylation in a conventional genetic engineering technique is overcome, the production of N-terminal acetyl thymosin extrasin by the genetic engineering technique is realized completely, and the method and the special engineering bacteria are very practical.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Method for preparing N-end acetylation modified thymosin alpha with recombined E. coli
The present invention discloses the preparation process of thynosin-alpha with acetylation modified N-end by using recombinant colibacillus. The preparation process includes obtaining thynosin-alpha gene, constructing recombinant expression vector containing thynosin-alpha, transforming prokaryotic cell, culturing prokaryotic cell and expressing thynosin-alpha, and separating and purifying thynosin-alpha with acetylation modified N-end. The present invention also discloses the process of utilizing recombinant colibacillus in preparing thynosin-alpha antigen with acetylation modified N-end and then cutting and separating to prepare thynosin-alpha-1 antigen with acetylation modified N-end, thynosin-alpha-2 antigen with acetylation modified N-end and similar matter. The thynosin-alpha with acetylation modified N-end has the functions of regulating immunity, cell proliferation, etc. and has wide application foreground in antivirus and antitumor.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
Owner:SCICLONE PHARM INT LTD
Method for preparing N-terminated acetylated thymosin alpha 1 and special engineering bacteria therefor
InactiveCN101497863AImprove expression levelMicroorganismsMicroorganism based processesAcetylationGene engineering
The invention discloses a method for preparing N-terminal acetylation extrasin alpha1, and special engineering bacteria thereof. The engineering bacteria is obtained in such a way that encoding genes of the extrasin alpha1 and encoding genes of N-terminal acetyl transferase are introduced to host strains. The N-terminal acetyl transferase is the protein of the following a or b: a) protein is composed of amino acid sequences shown by a sequence 7 in a sequence table; and b) protein is derived from the a) and is provided with the N-terminal acetyl transferase through the replacement and / or deletion and / or adding of one or a plurality of amino acid residue of the amino acid sequences shown by the sequence 7 in the sequence table. Talpha1 obtained through the preparation of the engineering bacteria is all N-terminal acetylized. The invention overcomes the defects of no acetylization or only partial N-terminal acetylization in a traditional gene project technology, thoroughly realizes N-terminal acetylization Talpha1 through a gene engineering technology, and has strong practical purposes.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Recombined extrasin alpha 1 two-strand body protein and preparation method thereof
InactiveCN101544693AEasy to separate and purifyInexpensive separation and purification processThymopoietinsPeptide/protein ingredientsEscherichia coliGlycine
The invention relates to a recombined extrasin alpha 1 two-strand body protein and a preparation method thereof. Glycin and serine are connected in series with bimolecular extrasin alpha 1 (T alpha 1), a connection mode is as follows: T alpha 1-Gly-Ser=T alpha 1, and an extrasin alpha 1 two-strand body gene expression vector is constructed by synthesized extrasin alpha 1 two-strand body genes so that extrasin alpha 1 which can not be directly expressed in colon bacillus can be efficiently expressed in the colon bacillus in a two-strand body way. The purified extrasin alpha 1 two-strand body protein has biological activity and can promote lymphocytes of small mice to proliferate, restrain tumor cell strains from proliferating and obviously restrain the tumor growth of tumor-bearing mice, thereby establishing a base for the further research and the extensive application of the extrasin alpha 1.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Method of utilizing biosynthesis and chemical modification technology in producing thymic hormone al monomer
InactiveCN1388133AOvercome the problem of difficult synthesis in vivoSimple processHormone peptidesChemical synthesisChemical modification
The present invention belongs to the field of biosynthesis and chemical modification technology. By means of bioengineering process, several thymosin genes are recombined and the recombinant gene is expressed in host cell to obtain high-expression thymosin fusion body. The fusion body is cracked and modified chemically to form thymosin alpha 1 monomer finally. The production process can produce thymosin alpha 1 identical with that produced chemically and is simple, low in cost and suitable for production in large scale. The present invention also provides the production process of several thymosin alpha 1 derivatives.
Owner:吴建中
Active fragment of thymosin alphal and its polyethylene glycol derivatives
The present invention relates to active fragment of natural or artificial amino acid substituted thymosin alpha-1 and its polyethylene glycol derivatives, their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, malignant melanoma, non-small cell lung carcinoma, SARS, etc.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Polyethlene glycol modifications of thymosin alpha-1
Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Preparation method for thymosin [alpha]1 and analogues thereof
The invention discloses a solid phase synthesis and purification process for thymosin [alpha]1 and analogues thereof, and belongs to the technical field of peptide synthesis. The process comprises the following steps of 1) taking a tricyclic amide linker resin as a carrier; 2) connecting side chain carboxyl groups of Fmoc-Asp-Y to amino groups of the resin after the resin is subjected to deprotection of Fmoc; 3) synthesizing residual amino groups in order in a solid phase by using a Fmoc strategy; 4) removing Fmoc protection groups from N-terminal amino protection groups, acetylating the N-terminal amino protection groups by using a DMF solution of Ac2O and DIPEA; 5) cutting by using a lysis reagent to obtain a crude peptide and precipitating the crude peptide with ether; and 6) separating the crude peptide by HPLC to obtain a pure product.
![Preparation method for thymosin [alpha]1 and analogues thereof](https://images-eureka.patsnap.com/patent_img/2385ecf7-e57c-422e-9b20-a2109c67ce6d/HDA0000134153780000011.PNG "Preparation method for thymosin [alpha]1 and analogues thereof")
![Preparation method for thymosin [alpha]1 and analogues thereof](https://images-eureka.patsnap.com/patent_img/2385ecf7-e57c-422e-9b20-a2109c67ce6d/HDA0000134153780000021.PNG "Preparation method for thymosin [alpha]1 and analogues thereof")
![Preparation method for thymosin [alpha]1 and analogues thereof](https://images-eureka.patsnap.com/patent_img/2385ecf7-e57c-422e-9b20-a2109c67ce6d/HDA0000134153780000031.PNG "Preparation method for thymosin [alpha]1 and analogues thereof")
Owner:CHANGCHUN BEYEL PHARMA
Treatment of hepatitis B infection with thymosin alpha 1 and lamivudine
InactiveCN1320041AEffective treatmentCombined securityPeptide/protein ingredientsPharmaceutical delivery mechanismDrug regimenFamciclovir
A method of treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral-effective amount of thymosin alpha 1 (Talpha1), an antiviral-effective amount of lamivudine, and optionally an antiviral-effective amount of famciclovir is disclosed.
Owner:SCICLONE PHARMACEUTICAL INC
Porcine circovirus type 2 Cap protein and thymosin alpha1 fusion protein and application
ActiveCN102827289AHighly effective immune responseImproving immunogenicityViral antigen ingredientsAntiviralsPorcine circovirusGenetic engineering
The invention relates to a porcine circovirus type 2 Cap protein, thymosin alpha1 fusion protein and an application, and an amino acid sequence of the fusion protein is shown as SEQ ID NO:1. The fusion protein can be used for preparing porcine circovirus type 2 subunit vaccine. The screened porcine circovirus type 2 Cap protein and a thymosin alpha1 gene having immunological enhancement effect are connected through a Lingker sequence to obtain the fusion protein. The genetic engineering subunit vaccine of the invention has good immunogenicity, and the immune response of piglet can be caused with high efficiency.
Owner:QINGDAO VLAND BIOTECH INC +1
Derivates of Polyethylene Glycol Modified Thymosin Alpha 1
Pharmaceutical compositions that include thymosin alpha 1 peptide derivatives modified at the C-terminal of the peptide chain with polyethylene glycol, and their pharmaceutical acceptable salts, are generally disclosed. Also, new methods used to prepare these thymosin alpha 1 peptide derivatives modified at the C-terminal of the peptide chain with polyethylene glycol are generally provided. The presently disclosed compounds and their salts can be prepared administered to humans to treat immune disease and can also be used in adjuvant treatment.
Owner:JIANGSU HANSOH PHARMA CO LTD
4 connecting body thymosin alpha 1 gene order and preparation method of transgene tomato
InactiveCN101451137AImprove immunityReduce manufacturing costFermentationHorticulture methodsDiseaseNucleotide
The invention discloses a 4*thymosin alpha1 gene sequence and a method for preparing transgenic tomato, which belongs to the field of gene engineering. The method comprises the following steps: a nucleotide sequence with bioactive thymosin alpha1 polypeptide is encoded according to a plant preferential codon, and has at least 75 percent of homology with a nucleotide sequence containing 16th to 408th nucleotides in SEQ ID NO.2; or the nucleotide sequence can be hybridized with the nucleotide sequence containing 16th to 408th nucleotides in the SEQ ID NO.2 under moderate stringent conditions. The invention also provides a method for expressing thymosin alpha1 functional protein by utilizing a plant system. A 4*T alpha1 gene expresses the important effect and application value of a product in improving the immunity of human bodies and preventing and treating human major diseases such as hepatitis, HIV, cancer and diabetes in eukaryotic cells.
Owner:SHANGHAI JIAO TONG UNIV
Recombined Talpha 1-BP5 fusion peptide, gene, engineering bacteria and application
InactiveCN103145853AHigh activityImprove immunityBacteriaMicroorganism based processesEscherichia coliThioredoxin
The invention discloses a recombined Talpha 1-BP5 fusion peptide, a gene, an engineering bacteria and an application. The recombined fusion peptide is prepared by fusing thymosin alpha 1 with Fabricius bursa pentapeptide BP5 through a soft Linker. The recombined Talpha 1-BP5 fusion peptide gene is inserted into an expression vector to transfer the escherichia coli so as to obtain the gene engineering bacteria for effectively express the Talpha 1-BP5 fusion peptide; the Talpha 1-BP5 fusion peptide is prepared through liquid cultivation and purification; and the thioredoxin of the fusion peptide is eliminated by using enterokinase with His tag at the N-end, and the fusion peptide is further subjected to affinity chromatography purification so as to obtain the single recombined Talpha 1-BP5 fusion peptide. The recombined Talpha 1-BP5 fusion peptide disclosed by the invention can be used as a novel polypeptide immunologic adjuvant which is used in match with vaccines, can effectively enhance the organism cell immune level and the body liquid immune level, and has wide application prospects.
Owner:HENAN UNIV OF SCI & TECH
Method for producing human thymosin alphal utilizing transgenic tomato
InactiveCN1891824AReduce manufacturing costIncrease contentFermentationVector-based foreign material introductionDiseaseHuman body
The invention relates to a method to produce human thymosin alpha 1 that uses transgene tomato as bio-reactor. It optimizes the nucleotide sequence of human thymosin alpha 1 according to plant preference codon. Compounding the gene and making it connect end to end to form tetrad, then, the plant expression transforming tomato expressed by thymosin alpha 1 cascading gene that is driven by cauliflower 35s promoter would be constructed. The thymosin alpha 1 would have important effect in vivo that could promote T cell function and the producing of special antibody and cell element. It could cure autoimmune diseases like lupus erythematosus, chronicity hepatitis B, etc. It could be also used as assistant medicine for curing cancer and tumor. The fruit containing thymosin alpha 1 could enhance human body immunity.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI +1
Chemically modified thymosin α1 and its synthesis method
ActiveCN103897053BIncrease concentrationDuration of increasing concentrationThymosin peptidesPeptide preparation methodsHuman bodyChemical structure
Owner:SHENZHEN INST OF ADVANCED TECH
Method and special engineering bacteria for producing N-terminal acetyl protein or polypeptide
The invention discloses a method and special engineering bacteria for producing N-terminal acetyl protein or polypeptide. The recombinant engineering bacteria capable of expressing transferase of archaebacteria on chromosomes are obtained by integrating the expression box of the transferase of archaebacteria onto the chromosomes of a host; the expression box for expressing the transferase of archaebacteria comprises a promoter and an archaebacteria transferase gene connected with the downstream of the promoter; and the nucleotide sequence of the archaebacteria transferase gene is represented by the sequence No.1 in a sequence list, and the amino acid sequence of the archaebacteria transferase gene is represented by a sequence No.2 in a sequence table. The engineering bacteria of the invention can directly produce complete N-terminal acetyl protein or polypeptide, such as thymosin extrasin alpha 1 and thymosin extrasin beta 4, the drawback of incompetence of acetylation or partial acetylation in a conventional genetic engineering technique is overcome, the production of N-terminal acetyl thymosin extrasin by the genetic engineering technique is realized completely, and the method and the special engineering bacteria are very practical.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
High secretion expression of recombination thymosin-alpha 1 in Escherichia coli and separation and purification therefor
ActiveCN1831126AHigh activityThe method steps are simpleBacteriaPeptide preparation methodsEscherichia coliChemical synthesis
The invention supplies a recombination thymosin alpha 1 gene, expression particle pKAT, engineering bacterium YKAT containing pKAT and filtered engineering strain YKAT-8, and the manufacture method for recombination thymosin alpha 1. It uses colibacillus preference codon, designing and combining recombination thymosin alpha 1 gene, recombining the upstream sequence, constructing pKAT and constructing and filtering YKAT-8. After fermenting and cultivating, directly excreting rT alpha-1 into culture medium, and the excreting quality could reach 500mg / L, and the purity could be over 95% after separating and purifying. It could sharply decrease producing cost and production cycle.
Owner:上海普洛创智医药科技有限公司 +1
GP thymosin alpha 1 and preparation method
InactiveCN1660899AImprove biological activityIncrease knot formation ratePeptide/protein ingredientsAntiviralsEscherichia coliChemical synthesis
A GP-thymin alpha 1 (GP-T alpha 1) is prepared through chemically synthesizing thymin alpha 1 gene, cloning it to karyogamy expression carrier pTRX, configuring fusion expression plasmid pTRX-GP-T alpha 1, adding proteinase ReScission Protease (3C) recognition site between pTRX and Talpha 1, expressing thioredoxin-T alpha 1 fusion protein, purifying by chromatography, enzyme severing of Pre Scission Protease (3C) to release GP-Talpha 1, affinity chromatography, and HPLC purifying. It can be used to prepare the medicines for treating viral hepatitis, tumor and AIDS.
Owner:SUN YAT SEN UNIV
Method for preparing thymosin α1 by condensation of liquid phase fragments
ActiveCN103665144BHigh purityHigh yieldHormone peptidesPeptide preparation methodsFluid phaseTarget peptide
Owner:NANTONG SHIMEIKANG PHARMA CHEM
Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene
ActiveCN106520807AImprove biological activityTherapeuticFungiThymosin peptidesPichia pastorisNucleotide
The invention discloses a thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and a preparation method of recombinant protein of the fusion protein gene. A nucleotide sequence of the reconstructed thymosin [alpha]1-porcine interferon [alpha] fusion protein gene provided by the invention is shown as SEQ ID NO.1. Meanwhile, the invention discloses a method for preparing the recombinant protein expressed by the gene and for conducting activity detection, wherein specifically, the method comprises such steps as reconstructing the thymosin [alpha]1-porcine interferon [alpha] fusion protein gene, cloning the gene and promoting secretory expression of the gene in pichia pastoris, preparing the recombinant protein and controlling fermentation culture conditions, improving such operating methods as the activity detection method and the like. The method provided by the invention is simple and easy to implement and is relatively low in cost; the efficient and stable secretory expression of the thymosin [alpha]1-porcine interferon [alpha] fusion protein in the pichia pastoris is achieved; and the expressed recombinant fusion protein is high in anti-viral activity and immune cell regulating activity levels; therefore, the invention lays a foundation for preparing green and no-residue biological products having functions of treating porcine viral diseases and immune regulation.
![Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene](https://images-eureka.patsnap.com/patent_img/b0005b72-a663-4cd4-a20d-446c43f2731e/HDA0001183134080000011.png "Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene")
![Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene](https://images-eureka.patsnap.com/patent_img/b0005b72-a663-4cd4-a20d-446c43f2731e/HDA0001183134080000012.png "Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene")
![Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene](https://images-eureka.patsnap.com/patent_img/b0005b72-a663-4cd4-a20d-446c43f2731e/HDA0001183134080000021.png "Thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and preparation method of recombinant protein of fusion protein gene")
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
New use of thymosin alpha1
InactiveCN101361962ALower fasting blood sugarEnhance glucose tolerancePeptide/protein ingredientsMetabolism disorderDiabrezideIslet cells
The invention discloses a new application of thymosin Alpha 1, which relates to the thymosin Alpha 1 and provides a new application of the thymosin Alpha 1. The thymosin Alpha 1 is used for preparing diabetes medicines. By the verification of animal experiments, the thymosin Alpha 1 can not only slow down the weight increase of a mouse, lower the normal fasting blood sugar of the mouse and obviously enhance the sugar tolerance of the mouse, but also prevent STZ from inducing the occurrence of diabetes of the mouse; besides, the thymosin Alpha 1 also plays an important role in protecting the structure of islet cells and the secretion level of insulin. The thymosin Alpha 1 can be used for maintaining normal glycometabolism and protecting the structure and functions of islet cells; by adopting the method of taking the thymosin Alpha 1 orally, the effect of obviously slowing down weight increase can be realized; therefore, the thymosin Alpha 1 can be applied to preparing drugs for preventing diabetes from occurring and treating diabetes and clinical practice.
Owner:XIAMEN UNIV +1
Treatment of glioblastoma with thymosin-alpha 1
InactiveUS20060166870A1Improve survivalReduce tumor burdenBiocideHormone peptidesAdjuvantGlioblastoma
Thymosin-α1 is used as an adjuvant in combination with carmustine (BCNU) as an effective treatment for malignant glioblastoma.
Owner:RHODE ISLAND HOSPITAL
Recombinant thymin alpha-1 and its prepn
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com